The FDA has approved two cell-based gene therapies for sickle cell disease, Casgevy from CRISPR/Vertex and Lyfgenia from Bluebird Bio, which are the first treatments available to individuals with SCD in the United States.
The Atlanta Voice is the leading news source dedicated to the well-being of Atlanta’s African American community.
The Atlanta Voice has stood as a pillar of truth, empowerment, and advocacy in Metro Atlanta for six decades. As we celebrate our 60th anniversary, we invite you to invest in independent journalism that serves YOU. Every dollar fuels our mission to keep our stories alive.
The FDA has approved two cell-based gene therapies for sickle cell disease, Casgevy from CRISPR/Vertex and Lyfgenia from Bluebird Bio, which are the first treatments available to individuals with SCD in the United States.